Central Serous Chorioretinopathy Clinical Trial
Official title:
Comparison of Different Doses of Verteporfin Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
This is a prospective, randomized and controlled clinical trial of photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). The patients who met the inclusion criteria were randomly divided into 50% dose PDT treatment group and 70% dose PDT treatment group. The primary treatment success rate and adverse event rate of the two groups were compared by optical coherence tomography (OCT), and then the best PDT treatment scheme for chronic CSC was summarized.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - 18-75 years old, regardless of gender; - Meet the diagnostic criteria of central serous chorioretinopathy; - The course of CSC (subject to the symptoms of this disease) is more than 3 months; - Patients with simultaneous diseases of both eyes were included in those with more subretinal fluid. Exclusion Criteria: - macular neuroretinal detachment caused by rhegmatogenous retinal detachment, uveitis, age-related macular degeneration, polypoid choroidal angiopathy and other fundus diseases; - a previous history of PDT treatment; - systemic hormone or local hormone nasal spray is being used, or hormone is stopped for less than 3 months. |
Country | Name | City | State |
---|---|---|---|
China | Peking University People's Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The complete absorption rate of subretinal fluid | The absorption of subretinal fluid was observed on optical coherence tomography at each follow up visit | 3 months after the primary PDT | |
Secondary | Central foveal thickness change after the PDT | The hight of central foveal thickness was measured on optical coherence tomography at each visit | 12 months after the PDT | |
Secondary | Subfoveal choroidal thickness change after the PDT | The hight of Subfoveal choroidal thickness was measured on optical coherence tomography at each visit | 12 months after the PDT | |
Secondary | Best corrected visual acuity change after the PDT | The BCVA was tested at each visit | 12 months after the PDT |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03497000 -
Effects of OCTA-guided PDT in Acute CSC
|
N/A | |
Recruiting |
NCT03692169 -
The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC
|
||
Not yet recruiting |
NCT02215330 -
A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy
|
Phase 2/Phase 3 | |
Completed |
NCT01990677 -
Eplerenone for the Treatment of Central Serous Chorioretinopathy
|
N/A | |
Completed |
NCT01971190 -
Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy
|
Phase 2 | |
Active, not recruiting |
NCT01710332 -
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
|
Phase 2 | |
Active, not recruiting |
NCT00403884 -
Selective RPE Laser Treatment (SRT) for Various Macular Diseases
|
N/A | |
Recruiting |
NCT05570591 -
Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy
|
N/A | |
Recruiting |
NCT05589974 -
Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
|
||
Completed |
NCT05104138 -
Eplerenone Versus PDT: Comparative Study by OCTA
|
||
Terminated |
NCT01982383 -
Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy
|
N/A | |
Completed |
NCT01880788 -
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
|
N/A | |
Completed |
NCT01327170 -
Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy
|
N/A | |
Completed |
NCT01019668 -
Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy
|
N/A | |
Recruiting |
NCT06346405 -
Central Serous Chorioretinopathy and Micropulse Laser Treatment
|
||
Recruiting |
NCT02141308 -
OCT in Rare Chorioretinal Diseases
|
||
Completed |
NCT01822561 -
Eplerenone for Central Serous Chorioretinopathy
|
Phase 2 | |
Completed |
NCT00802906 -
Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)
|
N/A | |
Withdrawn |
NCT05679180 -
Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE
|
N/A | |
Completed |
NCT05686421 -
Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations
|
N/A |